Table 6 Test properties of anti-RNAP for the prediction of various clinical manifestations in systemic sclerosis
Clinical manifestation a | Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) |
|---|---|---|---|---|
Diffuse subtype | 14.7% (11.2 to 18.8%) | 82.5% (73.4 to 89.5%) | 75.4% (63.5 to 84.9%) | 20.9% (17.0 to 25.4%) |
Joint contracture | 30.7% (23.8 to 38.3%) | 93.7% (90.2 to 96.2%) | 73.9% (61.9 to 83.8%) | 69.9% (65.0 to 74.5%) |
Synovitis | 22.5% (14.6 to 32.0%) | 86.7% (82.7 to 90.1% | 31.9% (21.2 to 44.2%) | 80.1% (75.7 to 84.0%) |
Myositisb | 50.0% (6.8 to 93.2%) | 85.0% (81.4 to 88.2%) | 2.9% (0.4 to 10.1%) | 99.5% (98.1 to 99.9%) |
Systemic hypertension | 21.6% (16.0 to 28.1%) | 89% (84.5 92.6%) | 59.4% (46.9 to 71.1%) | 60.3% (55.1 to 65.3%) |
Renal crisis | 70.8% (48.9 to 87.4%) | 87.8% (84.3 to 90.8%) | 24.6% (15.1 to 36.5%) | 98.2% (96.3 to 99.3%) |
Malignancyb (all types) | 21.9% (12.5 to 34.0%) | 85.8% (81.9 to 89.1%) | 20.3% (11.6 to 31.7%) | 86.9% (83.1 to 90.1%) |
Malignancyb,c (certain types) | 20.8% (10.5 to 35.0%) | 85.8% (81.9 to 89.1%) | 15.4% (7.6 to 2.6%) | 89.7% (86.2 to 92.6%) |
Malignancy within 5 years of SSc onsetc | 37.5% (15.2 to 64.6%) | 86.2% (81.7 to 90.0%) | 13.3% (5.1 to 16.8%) | 96.1% (92.9 to 98.1%) |